Compare · CI vs PSNL
CI vs PSNL
Side-by-side comparison of The Cigna Group (CI) and Personalis Inc. (PSNL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and PSNL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $74.45B, about 46.2x PSNL ($1.61B).
- Over the past year, CI is down 4.8% and PSNL is up 149.4% - PSNL leads by 154.2 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- CI has more recent analyst coverage (25 ratings vs 14 for PSNL).
- Company
- The Cigna Group
- Personalis Inc.
- Price
- $281.46-0.49%
- $15.39-1.25%
- Market cap
- $74.45B
- $1.61B
- 1M return
- -3.62%
- +58.99%
- 1Y return
- -4.78%
- +149.43%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 14
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Personalis Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.
Latest CI
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
- SEC Form 11-K filed by The Cigna Group
- The Cigna Group Foundation Invests $3 Million to Strengthen Youth Mental Health Through Nonprofits Across 10 States
Latest PSNL
- President and CMO Chen Richard exercised 100,000 shares at a strike of $2.44 and sold $1,515,000 worth of shares (100,000 units at $15.15) as part of a pre-agreed trading plan (SEC Form 4)
- Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
- Chief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,508,000 worth of shares (100,000 units at $15.08) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- CFO AND COO Tachibana Aaron sold $69,748 worth of shares (4,982 units at $14.00) as part of a pre-agreed trading plan and exercised 4,982 shares at a strike of $5.32 (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- CFO AND COO Tachibana Aaron exercised 51,251 shares at a strike of $7.48 and sold $675,488 worth of shares (51,251 units at $13.18) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Hall Christopher M exercised 100,000 shares at a strike of $1.61 and sold $1,315,000 worth of shares (100,000 units at $13.15) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Personalis Inc.
- SEC Form 144 filed by Personalis Inc.